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80 Abstract Patients with autoimmune diseases may have increased vascular risk leading 
to higher mortality rates. Novel imaging techniques are necessary for the early 
assessment and management of these patients. In this study, we compared 
augmentation index (AIx) and pulse wave velocity (PWV), indicators of arterial 
stiffness, to brachial arterial flow-mediated vasodilation (FMD) and common 
carotid artery intima–media thickness (ccIMT), standard indicators of 
endothelial dysfunction and atherosclerosis, respectively. We wished to assess 
the vascular status of autoimmune patients by using a novel, cheap, and 
reproducible technique, the arteriograph. Altogether, 101 patients with systemic 
autoimmune diseases including primary antiphospholipid syndrome, systemic 
sclerosis, rheumatoid arthritis, and polymyositis, all having various types of 
vasculopathies, as well as 36 healthy individuals were investigated. Arterial 
stiffness was assessed by a TensioClinic arteriograph, a recently validated 
technique. Brachial arterial FMD and ccIMT were determined using high-
resolution ultrasonography. Autoimmune patients exerted impaired FMD (3.7 ± 
3.8%), increased ccIMT (0.7 ± 0.2 mm), AIx (1.2 ± 32.2%), and PWV (9.7 ± 
2.4 m/s) in comparison to control subjects (FMD = 8.4 ± 4.0%; ccIMT = 0.6 ± 
0.1 mm; Aix = −41.1 ± 22.5%; PWV = 8.0 ± 1.5 m/s; p < 0.05). We found a 
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(R = −0.37; p = 0.00014). There were significant positive correlations between 
ccIMT and AIx (R = 0.34; p = 0.0009), ccIMT and PWV (R = 0.44; p < 0.0001), as 
well as AIx and PWV (R = 0.47; p < 0.0001). AIx, PWV, and ccIMT positively 
correlated and FMD negatively correlated with the age of the autoimmune 
patients. Arterial stiffness indicated by increased AIx and PWV may be strongly 
associated with endothelial dysfunction and overt atherosclerosis in patients 
with autoimmune diseases. Assessment of arterial stiffness, FMD, and ccIMT 
are reproducible and reliable noninvasive techniques for the complex 
assessment of vascular abnormalities in patients at high risk. 
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14 Abstract Patients with autoimmune diseases may have
15 increased vascular risk leading to higher mortality rates.
16 Novel imaging techniques are necessary for the early
17 assessment and management of these patients. In this study,
18 we compared augmentation index (AIx) and pulse wave
19 velocity (PWV), indicators of arterial stiffness, to brachial
20 arterial flow-mediated vasodilation (FMD) and common
21 carotid artery intima–media thickness (ccIMT), standard
22 indicators of endothelial dysfunction and atherosclerosis,
23respectively. We wished to assess the vascular status of
24autoimmune patients by using a novel, cheap, and reproduc-
25ible technique, the arteriograph. Altogether, 101 patients with
26systemic autoimmune diseases including primary antiphos-
27pholipid syndrome, systemic sclerosis, rheumatoid arthritis,
28and polymyositis, all having various types of vasculopathies,
29as well as 36 healthy individuals were investigated. Arterial
30stiffness was assessed by a TensioClinic arteriograph, a
31recently validated technique. Brachial arterial FMD and
32ccIMT were determined using high-resolution ultrasonogra-
33phy. Autoimmune patients exerted impaired FMD (3.7±
343.8%), increased ccIMT (0.7±0.2 mm), AIx (1.2±32.2%),
35and PWV (9.7±2.4 m/s) in comparison to control subjects
36(FMD=8.4±4.0%; ccIMT=0.6±0.1 mm; Aix=−41.1±
3722.5%; PWV=8.0±1.5 m/s; p<0.05). We found a significant
38negative correlation of FMD with AIx (R=−0.64; p<0.0001)
39and PWV (R=−0.37; p=0.00014). There were significant
40positive correlations between ccIMT and AIx (R=0.34; p=
410.0009), ccIMT and PWV (R=0.44; p<0.0001), as well as
42AIx and PWV (R=0.47; p<0.0001). AIx, PWV, and ccIMT
43positively correlated and FMD negatively correlated with the
44age of the autoimmune patients. Arterial stiffness indicated
45by increased AIx and PWV may be strongly associated with
46endothelial dysfunction and overt atherosclerosis in patients
47with autoimmune diseases. Assessment of arterial stiffness,
48FMD, and ccIMT are reproducible and reliable noninvasive
49techniques for the complex assessment of vascular abnor-
50malities in patients at high risk.
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54 Introduction
55 Vascular endothelial dysfunction is associated with the
56 development and progression of atherosclerosis (reviewed
57 in [1]). Endothelial dysfunction leads to increased vaso-
58 constriction, increased prothrombotic potential, and abun-
59 dant production of reactive oxygen intermediates (ROI) [1].
60 Classical cardiovascular risk factors, such as hypertension,
61 dyslipidemia, diabetes mellitus, and smoking, promote
62 oxidative stress and further enhance endothelial dysfunction
63 [1–3]. Atherosclerosis is considered to be an inflammatory
64 condition, as monocyte/macrophages, activated smooth
65 muscle cells, as well as inflammatory cytokines produced
66 by these cells are involved in its pathogenesis [4–6].
67 Accelerated atherosclerosis and increased cardiovascular
68 mortality have been described in systemic rheumatic
69 diseases, such as rheumatoid arthritis (RA), systemic lupus
70 erythematosus (SLE), antiphospholipid syndrome (APS),
71 systemic sclerosis (SSc), and dermatopolymyositis (DM/
72 PM) (reviewed in [7, 8]). Numerous epidemiological,
73 clinical, and laboratory investigations suggested that chron-
74 ic inflammation and immune dysregulation exert a key role
75 in accelerating atherosclerosis in these autoimmune dis-
76 eases [7–25]. Among pathogenic factors, classical, Fra-
77 mingham, as well as nontraditional, inflammatory risk
78 factors have been implicated in vascular disease underlying
79 autoimmunity [9–18, 21–25].
80 Different laboratory and imaging methods and novel
81 diagnostic procedures became very valuable for the
82 prediction of early atherosclerotic lesions in these patients
83 [29–36]. In 1992, Celermayer et al. [31] described the
84 assessment of flow-mediated vasodilation (FMD) of the
85 brachial artery. This technique is based on the principle that
86 because of shear forces due to flow increase in the brachial
87 artery, endothelial cells are activated, nitrogen monoxide
88 (NO) synthase and thus NO is abundantly produced by
89 endothelial cells eventually leading to vasodilation. In early
90 atherosclerosis, FMD indicating endothelial dysfunction
91 becomes abnormal first [31, 32]. Therefore, the reduced
92 dilation capability of the arteries can be observed at very
93 early stages [31–35]. By definition, if vasodilation does not
94 reach 5%, there is overt endothelial dysfunction [32]. The
95 assessment of the intima–media thickness of the common
96 carotid artery (ccIMT) is a standard method to assess overt
97 atherosclerosis [10, 18, 36]. Finally, pulse wave velocity
98 (PWV) and augmentation index (AIx) are parameters of
99 arterial stiffness and wave reflection. PWV and AIx may be
100 assessed by the recently validated new oscillometric
101 method, arteriograph [29, 30], as well as broadly accepted
102 tonometric (SphygmoCor) and piezoelectronic (Complior)
103 systems [29].
104 The major aim of this study was to assess autoimmune
105 patients with cardiovascular abnormalities using arterio-
106graph for the first time. We also wished to compare arterial
107stiffness assessed by arteriograph to FMD and ccIMT,
108standard indicators of endothelial dysfunction and overt
109atherosclerosis, respectively, in patients with systemic
110autoimmune diseases and healthy control individuals.
111Materials and methods
112Patients
113Altogether, 101 patients (77 females, 24 males; mean age=
11452.3±13.3 years) with various systemic autoimmune diseases
115undergoing regular follow-ups in our institution have been
116selected. This patient cohort included subjects with primary
117APS (n=50), SSc (n=24), PM (n=13), and RA (n=14). For
118comparison, 36 healthy individuals matched for sex (26
119females, 10 males), age (50.3±10.4 years), and Framingham
120risk factors served as controls. None of the autoimmune
121patients or controls smoked, had overt atherosclerosis,
122cardiovascular, cerebrovascular, or peripheral vascular dis-
123ease, hypertension, dyslipidemia, or other confounding
124conditions. None of the autoimmune patients received
125systemic corticosteroid or non/steroidal anti-inflammatory
126drug treatment at least 3 months before the study.
127Assessment of flow-mediated vasodilation
128Measurements were carried out on the patients’ right arms
129by using Hewlett-Packard (HP) Sonos 5500 high-resolution
130duplex ultrasound instrument (Soma Technology, Bloom-
131field, CT, USA) using a 10-MHz linear transducer and
132electrocardiogram gating as described before [10, 21, 31,
13334, 35]. Briefly, longitudinal images were taken, based on
134individual anatomical variability, 4–7 cm proximally from
135the cubital fossa. Systolic blood pressure was maintained
136over 50 mmHg for 5 min by inflating the cuff. Subse-
137quently, reactive hyperemia was induced by the quick
138release of the cuff. We detected and digitally saved the
139arterial diameter at rest and then the change in the diameter
140due to increased flow after 60 s. Results were analyzed
141offline by using the AVITA software (Gtech Information
142Systems, Oak Brook, IL, USA) [36]. The mean diameter
143was determined as the mean of three subsequent measure-
144ments performed synchronously with the R wave of the
145heart cycle [34, 35]. Change of FMD is presented as the
146percentage of increase or decrease in the arterial diameter
147after flow in comparison to the resting value. All assess-
148ments were performed by the same investigator in the
149morning hours, in an air-conditioned room at 21°C, after
150overnight fasting of the patient and resting for 30 min. All
151patients and control subjects were nonsmokers. In the
152morning of the measurements, participants were not
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F153 allowed to drink coffee, tea, or to take antioxidant vitamins.154 No vasoactive drugs were allowed 24 h before the assess-
155 ments. (The half-life of all vasoactive drugs administered
156 prior to the study was less than 24 h.)
157 Evaluation of the carotid artery intima–media thickness
158 ccIMT was determined by high-resolution Duplex ultraso-
159 nography using the HP Sonos 5500 instrument described
160 above equipped with 5–10 MHz linear transducer [10, 21,
161 36]. In brief, longitudinal and transverse section images
162 were taken of the carotid system. If no plaques could be
163 detected applying mediolateral transducer position, longi-
164 tudinal images were captured of the common carotid
165 arteries, 10 mm proximally from the carotid bulb. Images
166 were captured in the end-diastolic phase and ccIMT data
167 were evaluated offline using the AVITA software [36].
168 ccIMT was recorded as the distance between the first
169 (lumen–intima border) and the second (media–adventitia
170border) echogenic lines according to the leading edge
171method. On both sides, 10 measurements were performed;
172the mean of the individual values was calculated and results
173were presented in millimeters.
174Assessment of augmentation index and pulse wave velocity
175Measurements were carried out by using a TensioClinic
176arteriograph system (TensioMed Kft., Debrecen, Hungary)
177[29]. This technique is based on the fact that the contraction
178of the myocardium initiates pulse waves in the aorta. The
179first wave becomes reflected from the aortic wall at the
180bifurcation; therefore, a second, reflected wave appears as a
181late systolic peak. The morphology of this second, reflected
182wave depends on the stiffness of the large artery, the
183reflection time at 35 mmHg suprasystolic pressure of the
184brachial artery (RT S35) and the peripheral resistance-
185dependent amplitude.
186AIx is calculated from the amplitudes of the first and
187second waves. AIx is the pressure difference between the
188late systolic peak pressure and the early systolic peak
189pressure divided by the late systolic peak pressure. The
190arteriograph assesses this parameter from the oscillometric
191data obtained from the 35-mmHg suprasystolic pressure of
192the brachial artery [29, 33, 37].
193PWV is the quotient of the jugular fossa–symphysis
194distance and RT S35 in meters per second. The jugular
195fossa–symphysis distance is anatomically identical with the
196distance between the aortic trunk and the bifurcation. In
197order to have reproducible results, the patient needs a rest
198for at least 5 min before the assessment. In addition, the
199investigation room should be quiet [29, 33, 37].
t1.1 Table 1 Parameters of endothelial dysfunction, atherosclerosis, and
arterial stiffness in autoimmune patients and controls
t1.2 Patients (n=101) Controls (n=36) p value
t1.3 FMD (%) 3.66±3.82 8.39±4.03 <0.0001
t1.4 ccIMT (mm) 0.70±0.18 0.58±0.08 0.001
t1.5 AIx (%) 1.22±32.25 −41.15±22.47 <0.0001
t1.6 PWV (m/s) 9.66±2.40 8.00±1.46 0.0002
Values are the mean±standard deviation
FMD flow-mediated vasodilation, ccIMT common carotid artery
intima–media thickness, AIx augmentation index, PWV pulse wave
velocity
Fig. 1 Relationship of AIx and
FMD in autoimmune patients. A
significant negative correlation
is indicated between the mea-
sured parameters. R regression
coefficient, p level of statistical
significance
Clin Rheumatol
JrnlID 10067_ArtID 1118_Proof# 1 - 06/02/2009
AUTHOR'S PROOF!
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
200 Statistical analysis
201 For the analysis of endothelial dysfunction, AIx, and PWV,
202 Kolmogorov–Smirnov and Lilliefors tests were used.
203 Subsequently, we performed correlation analyses. In cases
204 of normal distribution (parametric), Pearson’s test was
205 performed; while in cases of non-normal distribution
206 (nonparametric) Spearman’s test was performed. When
207 significant correlation was found, the two independent
208 variables were plotted in a coordinate system, indicating the
209 type of correlation, the level of significance, and the value
210of the regression coefficient. p values less than 0.05 were
211considered statistically significant.
212Results
213Differences in FMD, ccIMT, AIx, and PWV in autoimmune
214patients and controls
215At baseline, there were no differences in the patients vs
216controls in the mean diameter of the brachial artery at rest
Fig. 2 Correlation between
FMD and PWV in autoimmune
patients. A significant negative
correlation was found between
FMD and FWV. R regression
coefficient, p level of statistical
significance
Fig. 3 Correlation between
ccIMT and AIx in autoimmune
patients. A significant positive
correlation was detected be-
tween ccIMT and AIx. R re-
gression coefficient, p level of
statistical significance
Clin Rheumatol
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217 (both 4.02 mm) and after provocation (4.17 vs 4.36 mm).
218 The mean value of FMD indicating endothelium-dependent
219 vasodilation was significantly decreased in the autoimmune
220 patients compared to healthy controls (3.66±3.82% vs 8.39
221 ±4.03%; p<0.0001). In contrast, ccIMT (0.70±0.18 vs
222 0.58±0.08 mm; p=0.001), AIx (1.22±32.25%. vs −41.15±
223 22.47%; p<0.0001), and PWV (9.66±2.40 vs 8.00±
224 1.46 m/s; p=0.0002) were significantly increased in
225 autoimmune patients vs controls (Table 1).
226Correlations between parameters of endothelial
227dysfunction, atherosclerosis, and arterial stiffness
228in autoimmune patients
229When correlation analysis was performed, FMD, a marker of
230endothelium-dependent vasodilation, exerted significant neg-
231ative correlations with either AIx (R=−0.64; p<0.0001)
232(Fig. 1) or with PWV (R=−0.37; p=0.00014) (Fig. 2). We
233could also confirm the negative correlation between FMD
Fig. 4 Correlation between
ccIMT and PWV in autoim-
mune patients. A significant
positive correlation was found
between ccIMT and PWV. R
regression coefficient, p level of
statistical significance
Fig. 5 Correlation between AIx
and PWV in autoimmune
patients. A significant positive
correlation was found between
AIx and PWV. R regression
coefficient, p level of statistical
significance
Clin Rheumatol
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234 and ccIMT (R=−0.48; p<0.0001) (data not shown). More-
235 over, positive correlations were found between ccIMT and
236 AIx (R=0.34; p=0.0009) (Fig. 3), ccIMT and PWV (R=
237 0.44; p<0.0001) (Fig. 4), as well as between the two
238 stiffness parameters, AIx and PWV (R=0.47, p<0.0001)
239 (Fig. 5). Among the four assessed parameters, AIx (R=0.42;
240 p<0.0001), PWV (R=0.34; p=0.0006), and ccIMT (R=0.72;
241 p<0.0001) positively correlated and FMD (R=−0.43; p<
242 0.0001) negatively correlated with the age of the patients
243 (data not shown).
244 Vasculopathy in different autoimmune diseases
245 Subsequently, subgroup analysis was performed in the
246 different autoimmune diseases. Although the number of
247 patients in each group was relatively small for statistical
248 analysis, and therefore, it is hard to draw definite
249 conclusions, in general, patients with APS, RA, SSc, or
250 PM had lower FMD and higher AIx in comparison to
251 controls (data not shown). In addition, although most
252 assessed parameters were not different in the various
253 disease subgroups, AIx was higher in RA (3.36±28.67%)
254 and SSc (11.4±27.2%) than in PM (−15.97±19.87%) (p=
255 0.0327 and p=0.0346, respectively) (data not shown).
256 Discussion
257 The pathogenesis of atherosclerosis involves numerous
258 autoimmune–inflammatory mechanisms [38], which may
259 explain the existence of accelerated atherosclerosis and
260 increased vascular morbidity in autoimmune rheumatic
261 diseases [7–25]. There is a need for novel diagnostic
262 techniques that can predict early endothelial dysfunction, as
263 well as overt atherosclerosis preclinically. These diagnostic
264 tools need to be fast, reproducible, and applicable on a
265 relatively large cohort of patients and should be able to easily
266 and cost-effectively identify patients at high risk for
267 cardiovascular morbidity and mortality. Although the evalu-
268 ation of ccIMT and FMD are suitable and reliable techniques
269 to assess carotid atherosclerosis and endothelial dysfunction,
270 respectively [10, 18, 31, 34–36, 39, 40], both methods are
271 relatively expensive and require special expertise. In contrast,
272 oscillometric arteriography used for the determination of
273 arterial stiffness is a simple and relatively cheap technique
274 performed in a simple automated system, which has recently
275 been validated by its comparison to two standard tonometric
276 (SphygmoCor) and piezoelectronic (Complior) systems [29,
277 30, 33]. Autoimmune patients have not been previously
278 tested for arterial stiffness using the arteriograph system.
279 Therefore, in the present study, we detected impaired
280 FMD, as well as increased ccIMT, AIx, and PWV in 101
281 autoimmune patients in comparison to 36 healthy control
282subjects. Impaired endothelium-dependent vasodilation and
283increased stiffness were observed in all patient subgroups
284including APS, RA, SSc, and PM. In addition, by studying
285arterial stiffness using arteriograph for the first time, both
286stiffness parameters, AIx and PWV, exerted negative
287correlation with FMD and positive correlation with ccIMT
288in the patient population. AIx and PWV also positively
289correlated with each other. Previously, various investigators
290reported accelerated atherosclerosis indicated by increased
291ccIMT in APS, RA, and SSc [7, 10, 13, 18, 21, 22, 34].
292Thus, while endothelial dysfunction (FMD) and accelerated
293atherosclerosis (ccIMT) have previously been described by
294us and others, we introduced arteriograph, a novel tool to
295assess arterial stiffness in autoimmune diseases. Arterial
296stiffness is closely associated with autoimmune inflamma-
297tion as we have recently reported in APS.
298In conclusion, the major aim of this study was to assess
299arterial stiffness of autoimmune patients for the first time
300using the arteriograph and to compare this method to other
301techniques used to assess endothelial dysfunction and
302atherosclerosis. Novel imaging methods are necessary for
303the early diagnosis and effective management of accelerated
304atherosclerosis seen in high-risk autoimmune patients. The
305arteriograph technique gives us a simple and cheap
306opportunity to assess the vasculature in these patients. Our
307data, as well as reports from other investigators, suggest
308that increasing arterial stiffness may be related to early
309endothelial dysfunction and overt atherosclerosis. As FMD
310and ccIMT assessments require special expertise and are
311relatively expensive and as arterial stiffness correlates with
312both FMD and ccIMT, the simple arteriograph technique
313may be used to screen patients at high risk for cardiovas-
314cular disease early. Thus, effective vasoprotective therapy
315can be initiated in order to prevent further cerebrovascular
316and cardiovascular complications.
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